Stock Markets

Daily coverage of equity markets, sectors, and major indices.

In-depth reporting on U.S. and global stock markets, including index performance, sector rotation, earnings reactions, volatility trends, and notable single-stock moves. Designed to help traders and investors understand what is driving price action across equities.

Articles

29,551 total articles

Scotiabank Singles Out WEC Energy as Top U.S. Utilities Pick; Mixed Readthroughs Across Peers

Scotiabank Singles Out WEC Energy as Top U.S. Utilities Pick; Mixed Readthroughs Across Peers

Scotiabank's second-quarter 2026 earnings review ranks WEC Energy Group as its preferred U.S. utilities selection, citing above-average EPS growth potential, meaningful upside to capital spending and a history of steady results. The bank's review of early Q2 reports shows a generally positive season, with most utilities beating estimates on the bot…

Marathon Petroleum Posts Strongest Quarterly Profit Since 2022 as Supply Disruptions Boost Margins

Marathon Petroleum Posts Strongest Quarterly Profit Since 2022 as Supply Disruptions Boost Margins

Marathon Petroleum reported a four-fold jump in second-quarter net income to $5.14 billion, well above analyst estimates, as disruptions to crude flows through the Strait of Hormuz and elevated global outages pushed refining margins sharply higher. The company saw refining and marketing margins double year-over-year, increased shareholder returns, …

Voyxact Preserves Kidney Function at Two Years in IgA Nephropathy, BTIG Says

Voyxact Preserves Kidney Function at Two Years in IgA Nephropathy, BTIG Says

BTIG analysts reviewed 24-month results from the VISIONARY trial of Voyxact (sibeprenlimab) in IgA nephropathy and found sustained improvement in estimated glomerular filtration rate (eGFR) versus placebo. The data met KDIGO benchmarks for slowing kidney decline. Otsuka has begun a rolling supplemental BLA and reported early commercial revenues and…

Jefferies Lowers Cigna to Hold Citing Mounting 2027 Earnings Risks

Jefferies Lowers Cigna to Hold Citing Mounting 2027 Earnings Risks

Jefferies downgraded Cigna from Buy to Hold and trimmed its price target to $307 from $336, arguing that several growing earnings risks and a paucity of near-term catalysts justify a more cautious stance despite a depressed valuation. The firm reduced its 2027 earnings estimate to $32.77 per share, about 1% below consensus, and highlighted potentia…

Salmonella Report Sparks Sharp Selloff in Chipotle Shares

Salmonella Report Sparks Sharp Selloff in Chipotle Shares

Chipotle Mexican Grill shares plunged after Minnesota health officials linked a salmonella outbreak affecting 110 people to jalapeños served at the chain’s restaurants in the state. The company removed the suspect jalapeños from impacted stores and is cooperating with investigators. The news erased part of a recent post-earnings rally and came amid…